公开(公告)号：EP3912623B1

公开(公告)日：2024-07-31

申请号：EP20175739.0

申请日：2020-05-20

IPC: A61K31/166 ,  A61K31/18 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/4523 ,  A61K31/519

CPC classification number: A61K31/4184 ,  A61K31/18 ,  A61K31/44 ,  A61K31/4523 ,  A61K31/166 ,  A61K31/519 ,  A61P31/14

公开(公告)号：EP4397306A1

公开(公告)日：2024-07-10

申请号：EP23150466.3

申请日：2023-01-05

Applicant: Dompe' Farmaceutici S.P.A.

Inventor： SCHMIDT, Enno ,  LUDWIG, Ralf ,  PATZELT, Sabrina ,  ARAMINI, Andrea ,  BRANDOLINI, Laura ,  COCCHIARO, Pasquale ,  BIANCHINI, Gianluca ,  DETTA, Nicola

IPC: A61K31/426 ,  A61K31/155 ,  A61K31/166 ,  A61K31/40 ,  A61K31/445 ,  A61P17/00 ,  A61P27/02 ,  A61P27/12 ,  A61P37/00 ,  A61K31/404 ,  A61K31/4453 ,  A61K39/395

CPC classification number: A61P27/02 ,  A61P27/12 ,  A61P17/00 ,  A61P37/00 ,  A61K31/445 ,  A61K31/155 ,  A61K31/166 ,  A61K31/40 ,  A61K31/426 ,  A61K31/404 ,  A61K31/4453 ,  C07K16/2896 ,  A61K2039/50520130101 ,  A61K2039/5420130101 ,  A61K2039/5520130101 ,  A61K2039/54520130101

Abstract: The invention relates to C5aRl inhibitors for use in the prevention and/or treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid.

公开(公告)号：EP4393489A1

公开(公告)日：2024-07-03

申请号：EP22849946.3

申请日：2022-07-29

Applicant: Provibio Co., Ltd.

Inventor： PARK, Seok Ju

IPC: A61K31/166 ,  A61K31/44 ,  A61K31/416 ,  A61K31/381 ,  A61K31/18 ,  A61K31/5377 ,  A61K31/197 ,  A61K31/222 ,  A61P37/00 ,  A61P37/06

CPC classification number: A61K31/222 ,  A61K31/18 ,  A61K31/5377 ,  A61P37/00 ,  A61K31/416 ,  A61K31/44 ,  A61K31/381 ,  A61P37/06 ,  A61K31/197 ,  A61K31/166

Abstract: The present invention relates to a novel benzene derivative and immunosuppressive-related use thereof. Specifically, it relates to a composition comprising a compound of Formula 1, its stereoisomer, solvate, hydrate, crystalline form, or pharmaceutically acceptable salt. The composition has preventive or therapeutic applications in immune disorders such as autoimmune diseases, transplant rejections, allergic diseases, and inflammatory conditions.

公开(公告)号：EP4125842B1

公开(公告)日：2024-06-05

申请号：EP21721706.6

申请日：2021-04-02

IPC: A61K31/166 ,  A61K31/4375 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K31/166 ,  A61K31/4375 ,  A61P35/00

公开(公告)号：EP3383377B1

公开(公告)日：2024-04-17

申请号：EP16820393.3

申请日：2016-12-01

IPC: A61K31/26 ,  A61K31/275 ,  A61P9/00 ,  C07D211/46

CPC classification number: A61K31/145 ,  A61K31/166 ,  A61K31/216 ,  A61K31/22 ,  A61K31/325 ,  A61K31/351 ,  A61K31/5375 ,  A61K31/26 ,  A61K31/27 ,  A61K31/4453 ,  A61K31/336 ,  A61K31/439 ,  A61K31/4425 ,  A61K31/452 ,  C07D211/46 ,  C07D213/04 ,  C07D213/30 ,  C07D213/65 ,  C07D295/13 ,  C07D303/36 ,  C07D453/02 ,  A61P9/00 ,  Y02A50/30

公开(公告)号：EP3391908A1

公开(公告)日：2018-10-24

申请号：EP16876001.5

申请日：2016-12-13

Applicant: Chong Kun Dang Pharmaceutical Corp.

Inventor： JOO, Min Jae ,  SEO, Hye Jin ,  PARK, Shin Jung

IPC: A61K47/10 ,  A61K9/08 ,  A61K31/166 ,  A61K31/519

CPC classification number: A61K9/08 ,  A61K31/166 ,  A61K31/519 ,  A61K47/10

Abstract: The present invention relates to a pharmaceutical composition with enhanced stability, containing pemetrexed or a salt thereof, and a preparation method therefor. The present invention provides an injection preparation in liquid form containing pemetrexed, capable of ensuring sufficient stability during circulation and storage by selection of an optimum material and setting of an optimum concentration range in order to secure the stability of pemetrexed. The present invention can provide a pemetrexed preparation which is readily commercially prepared, can prevent microbial contamination occurring during lyophilization or reconstitution, and has enhanced convenience of administration and stability.

公开(公告)号：EP3383378A1

公开(公告)日：2018-10-10

申请号：EP16823075.3

申请日：2016-12-01

Applicant: The Procter & Gamble Company ,  The Cleveland Clinic Foundation

Inventor： HAZEN, Stanley, Leon ,  GARCIA-GARCIA, Jose Carlos ,  GERBERICK, George, Franklin ,  WOS, John, August ,  STANTON, David, Thomas ,  INGLIN, Thomas, Alfred ,  REILLY, Michael ,  DEUTSCH, Angela, Jane ,  REED, Jodie, Michelle ,  CODY, David, Blair

IPC: A61K31/04 ,  A61K31/095 ,  A61K31/275 ,  A61K31/26

CPC classification number: A61K31/26 ,  A61K31/04 ,  A61K31/095 ,  A61K31/145 ,  A61K31/166 ,  A61K31/216 ,  A61K31/22 ,  A61K31/27 ,  A61K31/275 ,  A61K31/325 ,  A61K31/336 ,  A61K31/351 ,  A61K31/439 ,  A61K31/4425 ,  A61K31/4453 ,  A61K31/452 ,  A61K31/5375 ,  A61K45/06 ,  C07C331/20 ,  C07D211/46 ,  C07D213/04 ,  C07D213/30 ,  C07D213/65 ,  C07D295/13 ,  C07D303/36 ,  C07D453/02 ,  Y02A50/473

Abstract: The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

公开(公告)号：EP3337484A1

公开(公告)日：2018-06-27

申请号：EP16756762.7

申请日：2016-08-19

Applicant: Karus Therapeutics Ltd

Inventor： SHUTTLEWORTH, Stephen Joseph ,  WHALE, Andrew David

IPC: A61K31/519 ,  A61K31/5386 ,  A61K31/433 ,  A61K31/4365 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K31/5386 ,  A61K9/0053 ,  A61K31/166 ,  A61K31/18 ,  A61K31/4045 ,  A61K31/433 ,  A61K31/4365 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61K2300/00 ,  A61P29/00 ,  A61P35/02 ,  A61P37/06

Abstract: The invention relates to a pharmaceutical composition comprising at least one PI3K inhibitor of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor such as a compound of Formula II or a pharmaceutically acceptable salt thereof; or at least one PI3K inhibitor such as a compound of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor of Formula II or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP3150207A4

公开(公告)日：2018-05-23

申请号：EP15769676

申请日：2015-03-25

Applicant: NATIONAL UNIV CORPORATION TOTTORI UNIV ,  KANONCURE INC

Inventor： SHIOTA GOSHI ,  ITABA NORIKO ,  KANKI KEITA ,  SETO KENZO ,  SHIMIZU HIROKI ,  KOUNO YOHEI ,  KUNITA SHINYA ,  ADUMI ZYUNYA ,  SAKABE TOMOHIKO ,  ABE KENICHIRO ,  MORIMOTO MINORU ,  OKA HIROYUKI

IPC: A61K31/519 ,  A61K31/09 ,  A61K31/16 ,  A61K31/166 ,  A61P1/16 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/09 ,  A61K31/16 ,  A61K31/166

Abstract: A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.

公开(公告)号：EP2747561B1

公开(公告)日：2018-05-09

申请号：EP12825447.1

申请日：2012-08-23

Applicant: Evoke Pharma, Inc.

Inventor： D'ONOFRIO, Matthew, J. ,  GONYER, David, A. ,  CARLSON, Marilyn, R.

IPC: A61K31/166 ,  A61K9/00 ,  A61K47/12 ,  A61K47/18 ,  A61P1/00 ,  A61P43/00

CPC classification number: A61K31/166

Abstract: Nasal formulations of metoclopramide are administered for the treatment of symptoms associated with female gastroparesis. Also provided are methods of treating symptoms of female gastroparesis with nasal metoclopramide.